|
gptkbp:instanceOf
|
antineoplastic agent
nitrosourea compound
|
|
gptkbp:administeredBy
|
intravenous injection
implantable wafer (Gliadel)
|
|
gptkbp:approvedBy
|
gptkb:FDA
1977
|
|
gptkbp:ATCCode
|
L01AD01
|
|
gptkbp:brand
|
gptkb:BiCNU
gptkb:Gliadel
|
|
gptkbp:CASNumber
|
154-93-8
|
|
gptkbp:chemicalFormula
|
C5H9Cl2N3O2
|
|
gptkbp:color
|
yellow powder
|
|
gptkbp:contraindication
|
hypersensitivity to nitrosoureas
|
|
gptkbp:discoveredBy
|
gptkb:National_Cancer_Institute
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
15-30 minutes
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
carmustine
|
|
gptkbp:KEGGID
|
D00294
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antineoplastic agent
DNA crosslinking
|
|
gptkbp:meltingPoint
|
30-32°C
|
|
gptkbp:MeSH_ID
|
D002211
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
214.06 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL137
2578
DB00262
|
|
gptkbp:riskFactor
|
teratogenicity
carcinogenicity
|
|
gptkbp:routeOfAdministration
|
intravenous
intracranial implant
|
|
gptkbp:sideEffect
|
nausea
vomiting
liver toxicity
pulmonary toxicity
myelosuppression
kidney toxicity
|
|
gptkbp:solubility
|
slightly soluble in water
soluble in alcohol
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:synonym
|
gptkb:BCNU
|
|
gptkbp:UNII
|
U1QVF3175U
|
|
gptkbp:usedFor
|
leukemia
multiple myeloma
Hodgkin lymphoma
brain tumors
glioma
melanoma (intracranial metastases)
|
|
gptkbp:bfsParent
|
gptkb:multidrug_resistance-associated_protein_1
|
|
gptkbp:bfsLayer
|
6
|